American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

CATALYST PHARMACEUTICALS, INC. (CPRX)

$31.49 +0.03% NASDAQ: CPRX · 15-min delayed

CORAL GABLES, Florida
Public · NASDAQ: CPRX
182 employees

Visit website Follow

$3.8BMarket cap

$589.0MRevenue · FY2025

$214.3MNet income

182Employees

CPRXNASDAQ

2006IPO

About CATALYST PHARMACEUTICALS, INC.

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: CPRX
Employees: 182
IPO date: Nov 8, 2006
Headquarters: 355 ALHAMBRA CIRCLE
CORAL GABLES, Florida 33134
Phone: (305) 529-2522
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 5299004O0R5XXLA5H544

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: CPRX Nasdaq
SEC CIK: 1369568
LEI: 5299004O0R5XXLA5H544
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Catalyst Pharmaceuticals, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/catalyst-pharmaceuticals-inc/"><img src="https://americancompanies.com/badge/catalyst-pharmaceuticals-inc.svg" alt="Catalyst Pharmaceuticals, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow CATALYST PHARMACEUTICALS, INC. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $589.0M
Net income: $214.3M
Total assets: $1.1B
Market cap: $3.8B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: CPRX

$31.49 +0.03%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$19.13 $31.50

52-week range

Market cap: $3.8B
Shares outstanding: 121.5M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Nov 8, 2006

Catalyst Pharmaceuticals, Inc. (CPRX) Stock Price

Profitable — net income of $214.3M in FY2025.
Trading near its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review CATALYST PHARMACEUTICALS, INC..

Write a review

Newsroom

News about CATALYST PHARMACEUTICALS, INC.

Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals GlobeNewswire Inc. · 2026-07-16 · positive Family-Run Angelini Pharma Buys Catalyst Pharmaceuticals For Over 4 Billion Benzinga · 2026-05-07 · positive Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease Benzinga · 2026-05-07 · positive Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd. GlobeNewswire Inc. · 2026-05-07 · positive Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount Investing.com · 2026-03-11 · neutral Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? The Motley Fool · 2025-12-31 · neutral

News & sentiment via Polygon.io

FAQ

Catalyst Pharmaceuticals, Inc.: frequently asked questions

Is Catalyst Pharmaceuticals, Inc. an American company?

Catalyst Pharmaceuticals, Inc. is a US-based company headquartered in Coral Gables, Florida, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Catalyst Pharmaceuticals, Inc. headquartered?

Catalyst Pharmaceuticals, Inc. is headquartered in Coral Gables, Florida, United States.

Is Catalyst Pharmaceuticals, Inc. publicly traded?

Yes — Catalyst Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol CPRX on the NASDAQ.

What does Catalyst Pharmaceuticals, Inc. do?

Catalyst Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore